

**Diagnosis**

- When HIV RNA  $\geq 5,000$  copies/mL is detected, clinicians should consider that result a presumptive diagnosis of acute infection, even if the screening and antibody-differentiation tests are nonreactive or indeterminate. (A2)
- Clinicians should repeat HIV RNA testing to exclude a false-positive result when low-level quantitative results ( $< 5,000$  copies/mL) from an HIV RNA assay are reported in the absence of serologic evidence of HIV infection. (A2)
- **Note:** The absence of serologic evidence of HIV infection is defined as a nonreactive screening result (antibody or antibody/antigen combination) or a reactive screening result with a nonreactive or indeterminate antibody-differentiation confirmatory result.
- If a diagnosis of HIV infection is made on the basis of HIV RNA testing alone, the clinicians should collect a new specimen 3 weeks later to repeat HIV diagnostic testing according to the CDC HIV testing algorithm. (A2)
- If a diagnosis of acute infection is made on the basis of HIV RNA testing, then clinicians should recommend initiation of ART without waiting for serologic confirmation. (A2)
- When pregnant women are diagnosed with acute infection by HIV RNA testing, clinicians should not wait for results of a confirmatory test to initiate ART; initiation of ART is strongly recommended for pregnant women. (A2). [See the NYSDOH AI guideline *HIV Testing During Pregnancy and at Delivery*.]

**NYS Reporting Requirement and Partner Notification**

- Clinicians must report confirmed cases of HIV according to New York State Law (see *NYSDOH Provider Reporting and Partner Services* for more information about required reporting).
- Clinicians should offer assistance with partner notification and refer patients to other sources for partner notification assistance (Partner Services or CNAP). (A2)

**Prevention Following a Negative HIV Test**

- Clinicians should recommend PrEP for individuals, including adolescents, who do not have but are at high risk of acquiring HIV and have adequate renal function. (A1)

**ALL RECOMMENDATIONS** (continued from P.2) **P.3**

**Presentation**

- Clinicians should include acute HIV infection in the differential diagnosis for anyone (regardless of reported risk) with a flu- or mono-like illness (A3), especially when the patient:
  - Presents with a rash (A2)
  - Requests HIV testing (A3)
  - Reports recent sexual or parenteral exposure to a person with or at risk for HIV infection (A2)
- Presents with a newly diagnosed sexually transmitted infection (A2)
- Presents with aseptic meningitis (A2)
- Is pregnant or breastfeeding (A3)
- Is currently on pre- or post-exposure prophylaxis (PrEP or PEP) (A3)

Diagnostic HIV RNA testing should be considered for patients who present with compatible symptoms, particularly in the context of a sexually transmitted infection or a recent sexual or parenteral exposure with a partner known to have HIV or a partner whose HIV serostatus is not known. (A2)

**When Acute HIV Infection is Suspected**

- Clinicians should always perform a plasma HIV RNA assay in conjunction with an antigen/antibody combination screening test. (A2)
- Clinicians should use a 4th-generation antigen/antibody combination assay (preferred) as the initial HIV screening test according to the CDC's Recommended Laboratory HIV Testing Algorithm for Serum or Plasma Specimens.
- If the screening test is reactive, clinicians should perform an HIV-1/HIV-2 antibody-differentiation immunoassay to confirm HIV infection; Western blot is no longer recommended as the confirmatory test. (A2)
- **Note:** When rapid antibody screening is performed, including screening with a rapid 4th-generation test, a laboratory-based 4th-generation immunoassay is recommended in follow-up diagnostic HIV testing.

**ALL RECOMMENDATIONS** (continued from P.1) **P.2**

**ALL RECOMMENDATIONS** (continued from P.3) **P.4**

**Prevention Following a Negative HIV Test** *continued*

- HIV status should be confirmed by results of a negative 4th-generation (recommended) or 3rd-generation (alternative) HIV test within 1 week of planned PrEP initiation. (A3) [See the NYSDOH AI guideline *PrEP to Prevent Acquisition of HIV*.]

**Managing Acute HIV**

- Clinicians should recommend ART for all patients diagnosed with acute HIV infection. (A2)
- Clinicians should inform patients about the increased risk of transmitting HIV during acute HIV infection. (A2)
- As part of the initial management of patients diagnosed with acute HIV infection, clinicians should:
  - Consult with a provider experienced in the treatment of acute HIV infection (A3)
  - Obtain baseline HIV genotypic resistance testing, regardless of whether ART is being initiated (A2)
- **Patients taking PEP:** When acute HIV infection is diagnosed in a person receiving PEP, ART should be continued pending consultation with an experienced HIV care provider. (A3)
- **Patients taking PrEP:** When acute HIV infection is diagnosed in a person receiving PrEP, a fully active ART regimen should be recommended in consultation with an experienced HIV care provider. (A3)

**Initiating ART**

- If the clinician and patient have made a decision to initiate ART during acute HIV infection:
  - Treatment should be implemented with the goal of suppressing plasma HIV RNA to below detectable levels (A1)
  - Treatment should not be withheld while awaiting the results of recommended resistance testing; adjustments may be made to the regimen once resistance results are available (A3)
- Clinicians who do not have access to experienced HIV care providers should call the Clinical Education Initiative (CEI) Line at 1-866-637-2342.

**HIV CLINICAL RESOURCE**  **1/4-FOLDED GUIDE**  
VISIT [HIVGUIDELINES.ORG](http://HIVGUIDELINES.ORG) TO LEARN MORE OR VIEW COMPLETE GUIDE

 **DIAGNOSIS AND MANAGEMENT OF ACUTE HIV**  
NYSDOH AIDS INSTITUTE HIV CLINICAL GUIDELINE AUGUST 2018

**A NEW HIV DIAGNOSIS IS A CALL TO ACTION**


- In support of the NYSDOH AIDS Institute's January 2018 call to action for patients newly diagnosed with HIV, this committee stresses the following:
  - Immediate linkage to care is essential for any person diagnosed with HIV.
  - For the person with HIV, antiretroviral therapy (ART) dramatically reduces HIV-related morbidity and mortality.
  - Viral suppression helps to prevent HIV transmission to sex partners of people with HIV and prevents perinatal transmission of HIV.
- The urgency of ART initiation is even greater if the newly diagnosed patient is pregnant, has acute HIV infection, is  $\geq 50$  years of age, or has advanced disease. For these patients, every effort should be made to initiate ART immediately, and ideally, on the same day as diagnosis.
- All clinical care settings should be prepared, either on-site or with a confirmed referral, to support patients in initiating ART as rapidly as possible after diagnosis.

**ALL RECOMMENDATIONS** **P.1**

**NYS HIV Testing Requirements**

- According to NYS Law, physicians must offer an HIV test to all patients aged 13 years and older (or younger with risk) if a previous test is not documented, even in the absence of symptoms consistent with acute HIV. Although written consent to HIV testing is no longer required in NYS, patients must be given the opportunity to decline, and verbal consent must be documented in the medical record.

**Figure 2. Diagnostic Testing for Acute HIV Infection**



**KEY POINTS**

- The diagnosis of acute HIV infection requires a high degree of clinical awareness. The nonspecific signs and symptoms of acute HIV infection are often not recognized.
- Diagnostic HIV RNA testing should be considered for patients who present with compatible symptoms (see *Acute Retroviral Syndrome* in the full guideline), particularly in the context of a sexually transmitted infection or a recent sexual or parenteral exposure with a partner known to have HIV or a partner whose HIV serostatus is not known.
- A negative screening test in response to suspected acute HIV infection is an opportunity to offer or refer the individual for PrEP. See the NYSDOH AI guideline *PrEP to Prevent HIV Acquisition*.
- Patients undergoing HIV testing who are not suspected to have acute infection should receive screening according to the standard protocol. Patients with clinical signs or symptoms of acute retroviral syndrome or who are at high risk for acute infection should receive HIV screening and HIV RNA testing simultaneously.
- A positive HIV RNA assay is a preliminary diagnosis of HIV; ART should be recommended while waiting for confirmatory testing.
- Individual laboratories have internal protocols for reporting HIV tests with preliminary results: *indeterminate*, *inconclusive*, *nondiagnostic*, and *pending validation* are among the terms used when preliminary results cannot be classified definitively. The clinician should contact the appropriate laboratory authority to determine the significance of the nondefinitive results and the supplemental testing that would be indicated. This is of particular importance in tests from patients with suspected acute HIV infection. Clinicians should become familiar with the internal test-reporting policies of their institutions.
- If the decision to initiate treatment has been made, therapy should not be withheld while awaiting the results of resistance testing. Adjustments may be made to the regimen once resistance results are available.

**Notes:**

- Viremia will be present several days before antibody detection
- The absence of serologic evidence of HIV infection is defined as nonreactive screening result (antibody or antibody/antigen combination) or a reactive screening result with a nonreactive or indeterminate antibody-differentiation confirmatory result.
- Serologic confirmation as defined by the CDC HIV testing algorithm. Western blot is no longer recommended as the confirmatory test because it may yield an indeterminate result during the early stages of seroconversion and may delay confirmation of diagnosis.
- No further testing is indicated
- See the NYSDOH AI guidelines on ART: [www.hivguidelines.org/antiretroviral-therapy/](http://www.hivguidelines.org/antiretroviral-therapy/)



← Use this code with your phone's QR code reader to go directly to a mobile-friendly version of the guideline.

■ This 1/4-Folded Guide is a companion to the New York State Department of Health AIDS Institute guideline *HIV Testing*. The full guideline is available at [www.hivguidelines.org](http://www.hivguidelines.org).